Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Key Takeaways The S&P 500 added 0.8% on Thursday, July 3, 2025, reaching a record closing high as a strong jobs report helped ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. TaxStatus is the only firm to provide the comprehensive information advisors need to ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Rahway, New Jersey Thursday, July 3, 2025, 09:00 Hrs [IST] ...

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

ZENITH was the first of its kind in PAH to focus purely on hard outcomes like death, transplant, or long-term hospitalization ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...